359 related articles for article (PubMed ID: 29115879)
1. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
6. Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation.
Joshi G; Nayyar H; Kalra S; Sharma P; Munshi A; Singh S; Kumar R
Chem Biol Drug Des; 2017 Nov; 90(5):995-1006. PubMed ID: 28544624
[TBL] [Abstract][Full Text] [Related]
7. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
9. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
14. Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors.
Han J; Henriksen S; Nørsett KG; Sundby E; Hoff BH
Eur J Med Chem; 2016 Nov; 124():583-607. PubMed ID: 27614407
[TBL] [Abstract][Full Text] [Related]
15. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent Antiproliferative Agents Targeting EGFR Tyrosine Kinase Based on the Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine Scaffold.
Aziz YM; Said MM; El Shihawy HA; Tolba MF; Abouzid KA
Chem Pharm Bull (Tokyo); 2015; 63(12):1015-28. PubMed ID: 26633023
[TBL] [Abstract][Full Text] [Related]
18. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
